Afscin Djahandideh Sheijani

Dr. Afscin Djahandideh Sheijani

S.C. Gastroenterologia ed Endoscopia Digestiva Osp. Santa Corona di Pietra Ligure
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EMElisa Marabotto
Elisa Marabotto
GPGaia Pellegatta
Gaia Pellegatta
ASAfscin Djahandideh Sheijani
Afscin Djahandideh Sheijani
SZSebastiano Ziola
Sebastiano Ziola
PZPatrizia Zentilin
Patrizia Zentilin
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
In the last 30 years, we have witnessed a rapid increase in the incidence and prevalence of esophageal cancer in many countries around the word. However, despite advancements in diagnostic technologies, the early detection of this cancer is rare, and its prognosis remains poor, with only about 20% of these patients surviving for 5 years. The two major forms are the esophageal squamous cell carcinoma (ESCC), which is particularly frequent in the so-called Asian belt, and the esophageal adenocarcinoma (EAC), which prevails in Western populations. This review provides a summary of the epidemiological features and risk factors associated with these tumors. Moreover, a major focus is posed on reporting and highlighting the various preventing strategies proposed by the most important international scientific societies, particularly in high-risk populations, with the final aim of detecting these lesions as early as possible and therefore favoring their definite cure. Indeed, we have conducted analysis with attention to the current primary, secondary and tertiary prevention guidelines in both ESCC and EAC, attempting to emphasize unresolved research and clinical problems related to these topics in order to improve our diagnostic strategies and management.

22 July 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
EMElisa Marabotto
Elisa Marabotto
DFDiego Ferone
Diego Ferone
ASAfscin Djahandideh Sheijani
Afscin Djahandideh Sheijani
LVLara Vera
Lara Vera
SZSebastiano Ziola
Sebastiano Ziola
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
Purpose: to determine lactose intolerance (LI) prevalence in women with Hashimoto’s thyroiditis (HT) and assess the impact of LI on LT4 replacement dose. Methods. consecutive patients with HT underwent Lactose Breath Test and clinical/laboratory data collection. Unrelated gastrointestinal disorders were carefully ruled out. Lactose-free diet and shift to lactose-free LT4 were proposed to patients with LI. Results: we enrolled 58 females (age range, 23–72 years) with diagnosis of HT. In total, 15 patients were euthyroid without treatment, and 43 (74%) euthyroid under LT4 (30 of them with a LT4 formulation containing lactose). Gastrointestinal symptoms were present in 84.5% of patients, with a greater prevalence in change in bowel habits in lactose-intolerant patients (p < 0.0001). The cumulative LT4 dose required did not differ in patients with or without LI. No significant difference in both TSH values and LT4 dose were observed in patients shifted to lactose-free LT4 and diet at 3 and 6 months compared to baseline. Conclusion: the prevalence of LI in patients with HT was 58.6%, not different from global prevalence of LI. In the absence of other gastrointestinal disorders, LI seems not to be a major cause of LT4 malabsorption and does not affect the LT4 required dose in HT patients.